Skip to main content

Marketing authorisation for Covishield will be considered when application is received, says EU agency

New Delhi: The Covishield vaccine "does not currently have a marketing authorisation" in Europe and the matter would be considered when an application is received for it, the European Medicines Agency (EMA) said on Monday.

People vaccinated with Covishield, manufactured by Pune-based Serum Institute of India (SII), are unlikely to be eligible to travel to the European Union member states under the 'Green Pass' scheme as the vaccine is yet to be cleared by the EMA.

The EU Digital COVID certificate or 'Green Pass' will be mandatory to travel to European countries and the document is likely to serve as proof that a person is vaccinated against COVID-19.

Travel under 'Green Pass' to non-EU citizens may be rolled out in a phased manner from 1 July.

However, individual European Union member countries may have separate rules and norms for travellers.

The EMA has already approved four COVID-19 vaccines which included Vaxzevria, the AstraZeneca vaccine manufactured in the UK and EU-member countries.

The SII makes Covishield in India with a licence from AstraZeneca.

"The only COVID-19 vaccine from AstraZeneca for which a marketing authorisation application was submitted to and evaluated by EMA, leading to its authorisation in the EU, is Vaxzevria," Alessandro Faia, a spokesperson of the EMA said.

"In the EU, the vaccine called Covishield does not currently have a marketing authorisation. Even though it may use an analogous production technology to Vaxzevria (the COVID-19 AstraZeneca vaccine authorised in the EU), Covishield as such is not currently approved under EU rules," the official said.

Explaining the reason, the official said even tiny differences in the manufacturing conditions can result in differences in the final product.

"This is because vaccines are biological products. Even tiny differences in the manufacturing conditions can result in differences in the final product, and EU law, therefore, requires the manufacturing sites and production process to be assessed and approved as part of the authorisation process," the spokesperson said.

"Should we receive a marketing authorisation application for Covishield or should any change to the approved manufacturing sites for Vaxzevria be approved, we would communicate about it," he said.

The official clarified that the EMA is not responsible for any decision regarding travelling into the EU and the travelling conditions associated with COVID-19 vaccination, such as the EU Digital COVID certificate.

"This is a matter for the European Commission and for individual member states," the official added.



from Firstpost India Latest News https://ift.tt/3qw3ZGB
Labels:

Comments

Post a Comment

Popular posts from this blog

COVID-19 vaccination: Registration for citizens above 18 years of age starts today on CoWin, Aarogya Setu portals

The registration for COVID-19 vaccination for people above the age of 18 years in India started from today ( Wednesday, 28 April ). Those who are eligible for vaccination can register themselves on two applications, namely CoWin and Aarogya Setu, to book their slots for taking the vaccine jab. For those above the age of 18, coronavirus vaccination will start from 1 May. People above the age of 18 can take the following steps to register for the vaccination: Step 1 : Open the play store to download the CoWin app or visit CoWin.gov.in Step 2 : Register on the portal using your mobile number. You will receive an OTP. Enter it to complete the registration Step 3 : You will have to enter your personal details including the number of your photo identification Step 4 : After the registration, select the date, time, and venue for your COVID-19 vaccination Step 5 : Visit the vaccination centre with your appointment slip and receive your first jab Once a person receives the first jab, th...
Post a Comment
Read more

7 leopard cubs die at Bengaluru biological park after virus attack: Report

Seven leopard cubs have died at Bannerghatta Biological Park in Bengaluru after being infected by a highly contagious virus, officials said on Tuesday. Feline panleukopenia (FP) is a viral disease of cats caused by the feline parvovirus. Kittens are most severely affected by the virus, they said. The seven cubs were aged between three and eight months. All of them were vaccinated but succumbed during the course of treatment. According to officials, the first outbreak was reported on August 22. Executive Director of Bannerghatta Biological Park, AV Surya Sen said though the seven cubs were vaccinated, they were still infected. “It is now under control and in the last 15 days, no deaths have been reported. We have completely broken the chain and taken all necessary measures. We followed all the required procedure and also held discussions with all our senior veterinarians. All correct course of action was taken. Also, we have ensured hygiene of the entire zoo and the rescue centre wa...
Post a Comment
Read more

Power supply, healthcare facilities remain concern for Asia’s oldest monastery

Uninterrupted power supply and access to medical care remain important worries for Asia’s oldest monastery in Arunachal Pradesh’s Tawang. The waste left behind by the monastery’s expanding number of tourists has also become a source of concern for Abbot Shedling Tulku Thupten Tendar Rinpoche, the monastery’s chief. The Rinpoche, who has been the head of the Tawang Monastery for a year, is pleased with the monks and learners under him, but he is concerned about other facilities accessible to them. Tawang Monastery is Asia’s second largest and oldest. It was established between 1680 and 1681. Speaking to PTI in his native Tibetan through an interpreter, Rinpoche said, “The monks of our monastery are much disciplined and concentrate on their studies. They have been following the laid-down traditions well enough. “For us, one major issue is healthcare facilities. In case of any health-related emergency, our monks have to travel to Guwahati or Tezpur. If the government can ensure simil...
Post a Comment
Read more